Literature DB >> 20861163

Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4.

Alexander M Vezeridis1, Konstantinos Drosatos, Vassilis I Zannis.   

Abstract

We have used adenovirus-mediated gene transfer in apolipoprotein (apo)E(-/-) mice to elucidate the molecular etiology of a dominant form of type III hyperlipoproteinemia (HLP) caused by the R142C substitution in apoE4. It was found that low doses of adenovirus expressing apoE4 cleared cholesterol, whereas comparable doses of apoE4[R142C] greatly increased plasma cholesterol, triglyceride, and apoE levels, caused accumulation of apoE in VLDL/IDL/LDL region, and promoted the formation of discoidal HDL. Co-expression of apoE4[R142C] with lecithin cholesterol acyltransferase (LCAT) or lipoprotein lipase (LPL) in apoE(-/-) mice partially corrected the apoE4[R142C]-induced dyslipidemia. High doses of C-terminally truncated apoE4[R142C]-202 partially cleared cholesterol in apoE(-/-) mice and promoted formation of discoidal HDL. The findings establish that apoE4[R142C] causes accumulation of apoE in VLDL/IDL/LDL region and affects in vivo the activity of LCAT and LPL, the maturation of HDL, and the clearance of triglyceride-rich lipoproteins. The prevention of apoE4[R142C]-induced dyslipidemia by deletion of the 203-299 residues suggests that, in the full-length protein, the R142C substitution may have altered the conformation of apoE bound to VLDL/IDL/LDL in ways that prevent triglyceride hydrolysis, cholesterol esterification, and receptor-mediated clearance in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861163      PMCID: PMC2999928          DOI: 10.1194/jlr.M008409

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  50 in total

1.  Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion.

Authors:  K E Kypreos; K W van Dijk; A van Der Zee; L M Havekes; V I Zannis
Journal:  J Biol Chem       Date:  2001-02-09       Impact factor: 5.157

Review 2.  Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer.

Authors:  Vassilis I Zannis; Angeliki Chroni; Kyriakos E Kypreos; Horng-Yuan Kan; Thais Borges Cesar; Eleni E Zanni; Dimitris Kardassis
Journal:  Curr Opin Lipidol       Date:  2004-04       Impact factor: 4.776

3.  Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT.

Authors:  Kyriakos E Kypreos; Vassilis I Zannis
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

4.  The central helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type ApoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo.

Authors:  Angeliki Chroni; Tong Liu; Irina Gorshkova; Horng-Yuan Kan; Yoshinari Uehara; Arnold Von Eckardstein; Vassilis I Zannis
Journal:  J Biol Chem       Date:  2002-12-17       Impact factor: 5.157

5.  The effects of mutations in helices 4 and 6 of ApoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport.

Authors:  Tong Liu; Monty Krieger; Horng-Yuan Kan; Vassilis I Zannis
Journal:  J Biol Chem       Date:  2002-03-06       Impact factor: 5.157

6.  Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency.

Authors:  Angeliki Chroni; Adelina Duka; Horng-Yuan Kan; Tong Liu; Vassilis I Zannis
Journal:  Biochemistry       Date:  2005-11-01       Impact factor: 3.162

7.  LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN.

Authors:  Georgios Koukos; Angeliki Chroni; Adelina Duka; Dimitris Kardassis; Vassilis I Zannis
Journal:  Biochemistry       Date:  2007-08-21       Impact factor: 3.162

8.  A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice.

Authors:  Konstantinos Drosatos; Despina Sanoudou; Kyriakos E Kypreos; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Biol Chem       Date:  2007-04-24       Impact factor: 5.157

9.  Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins.

Authors:  R J Havel; J P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  1973-07       Impact factor: 11.205

10.  Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain.

Authors:  Xiaoping Li; Kyriakos Kypreos; Eleni E Zanni; Vassilis Zannis
Journal:  Biochemistry       Date:  2003-09-09       Impact factor: 3.162

View more
  3 in total

1.  Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL.

Authors:  Andreas K Kateifides; Irina N Gorshkova; Adelina Duka; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2011-04-19       Impact factor: 5.922

2.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

Review 3.  Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.

Authors:  Britt E Heidemann; Charlotte Koopal; Alexis Baass; Joep C Defesche; Linda Zuurbier; Monique T Mulder; Jeanine E Roeters van Lennep; Niels P Riksen; Christopher Boot; A David Marais; Frank L J Visseren
Journal:  Clin Genet       Date:  2022-08-22       Impact factor: 4.296

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.